A study in the Journal of the American Medical Association (JAMA, April 6,2011)) sheds new light on taking estrogen. Here is what it means to you.
Estrogen versus Estrogen and Progesterone and Uterine Cancer
Like all medications, estrogen is a powerful hormone with benefits and risks that have to be weighed and personalized for each woman. Forty years ago estrogen was so popular and considered so beneficial that almost all women were encouraged to take it from the time of menopause until death. Unfortunately, it was found that estrogen alone can cause cancer of the uterus. Women who have had a hysterectomy and had their uterus removed don’t have this problem.
Then researchers discovered that women who take daily estrogen combined with progesterone for at least 10 days of the month did not get uterine cancer. There were some risks of blood clots and strokes, but overall it was believed that estrogen plus progesterone protected the uterus from uterine cancer and estrogen helped to prevent heart disease. The heart disease part of this changed with more research.
OUR BODIES ARE DIFFERENT
Surely women are women? Of course women have specific similarities, but it is their differences that serve to drive home the subtitle of this book, namely, in contemporary menopause management, one size does not fit all! I will return to this subject shortly, but first it is necessary to provide the background information to menopause and its appropriate management.
Let me emphasize one point immediately. Until the late 1990’s, whenever the word menopause came up in some medical circles, it was almost universally equated with another term “Hormone Replacement Therapy (HRT), as if the one could not get along without the other. This implied you could not be fully active or healthy after menopause unless you took hormonal medication. Today, a new philosophy prevails.
Miami, FL and New York, NY, September 18, 2013 – Noven Pharmaceuticals, Inc., today announced the publication of results from its two Phase 3 clinical studies in Menopause, the peer-reviewed, scientific journal of The North American Menopause Society. Brisdelle™, paroxetine capsules, 7.5 mg/day, was approved by the United States Food and Drug Administration in June 2013, for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause, commonly referred to as hot flashes and night sweats.